Numinus Wellness Inc. (TSX: NUMI)
Canada
· Delayed Price · Currency is CAD | Market Cap | 18.94M |
| Revenue (ttm) | 23.10M |
| Net Income (ttm) | -26.99M |
| Shares Out | 316.46M |
| EPS (ttm) | -0.10 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,042,148 |
| Open | 0.0700 |
| Previous Close | 0.0700 |
| Day's Range | 0.0650 - 0.0750 |
| 52-Week Range | 0.0650 - 0.2750 |
| Beta | 1.55 |
| Analysts | n/a |
| Price Target | 1.10 (+1,471.43%) |
| Earnings Date | Jul 15, 2024 |
About Numinus Wellness
Numinus Wellness Inc. provides psychedelic-assisted psychotherapy products and services in Canada and the United States. The company operates through Clinical Research Operations, Canadian Clinic Network, and U.S Clinic Network segments. The Clinical Research Operations segment offers clinical research management services to academic institutions and biotechnology companies. The Canadian Clinic Network segment provides clinical services, including traditional therapy and counseling, ketamine-assisted therapies for depression, psychedelic-assist... [Read more]
Financial Performance
In 2023, NUMI's revenue was 23.18 million, an increase of 256.95% compared to the previous year's 6.49 million. Losses were -30.26 million, -32.59% less than in 2022.
Financial StatementsNews
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support
Numinus focuses resources on high-growth US operations, enhancing profitability Agreement with Field Trip Health to transition Canadian clinic operations, focusing on collaborative growth and therapis...
Cedar Clinical Research selected as clinical research site for Cybin's Phase 3 Study of CYB003
VANCOUVER, BC , April 17, 2024 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behaviora...
Numinus Wellness Q2 2024 Revenue Declines Amid Clinic Reshuffling And Expected Industry Trends
Psychedelics healthcare company Numinus Wellness (OTCQX: NUMIF) shared its unaudited, condensed and consolidated interim financial results for the three and six months ended February 29, 2024. Q2 sho...
Numinus Wellness Provides Corporate Update
Numinus sharpens its focus on streamlining operations and maximizing shareholder returns through a focus on U.S. operations and strategic adjustments in its Canadian market presence. Focusing on the N...
Numinus Wellness reports Q2 results
Numinus Wellness press release (NUMIF): Q2 cash position of C$6.6 million as of February 29, 2024. Revenue of C$5M (-6.5% Y/Y). Enrolment in Numinus training programs doubled to over 1,400
Numinus Wellness Q2 Earnings Preview
Numinus Wellness Inc. Announces Second Quarter Fiscal 2024 Results
Q2 Fiscal 2024 Highlights Cash position of $6.6 million as of February 29, 2024 Gross profit of $0.5 million, a 22.7% decline over Q1 2024 Revenue of $5.0 million, a 15.4% decline over Q1 2024 Enrolme...
Numinus to Host Q2 Fiscal 2024 Results Conference Call on April 15, 2024
VANCOUVER, BC, April 9, 2024 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioural...
Two Top Biotechs Forge MDMA Supply Deals For Clinical Research
Two separate deals hit the wires on Tuesday. One is PharmAla Biotech's (OTC: MDXXF) with Numinus Wellness (OTC: NUMIF) for a group therapy model with MDMA, the other is Optimi Health's (OTCQX: OPTHF...
PharmAla Biotech signs sale agreement with Numinus Wellness
Utah Hospitals Will Soon Provide Psilocybin And MDMA Therapy For Mental Health Conditions
Providers at Utah's two largest healthcare systems may now treat patients with psilocybin and MDMA as part of a pilot program created by a proposal-turned-law that will take effect as early as May 1, ...
Numinus Wellness Submits Clinical Trial Application
VANCOUVER, BC , March 20, 2024 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behaviora...
Numinus Wellness Provides Corporate Update
Announces Date of Annual General Meeting, Appointment of Directors, and Interim Chief Financial Officer VANCOUVER, BC , March 12, 2024 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company")...
Numinus Wellness Congratulates MindMed on Positive Results from Phase 2B Clinical Trials of MM120 for Generalized Anxiety Disorder
VANCOUVER, BC , March 8, 2024 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral...
Numinus Wellness Inc. Announces $6 Million Bought Deal Public Offering with Leads Orders from MAPS and Integrated V.C.
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
/C O R R E C T I O N from Source -- Numinus Wellness Inc./
In the news release issued 01-Feb-2024 at 7:00 ET by Numinus Wellness Inc. over CNW Group, we are advised by the company that changes were made in their press release. The complete, corrected release ...
Numinus Wellness Divests of Holdings in Alto Neuroscience Inc.
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated September 25, 2023 to its short form base shelf prospectus dated June 27, 2023. ...
Numinus Wellness Continues Tight Expense Management With Strategic Reviews Underway
Psychedelics mental healthcare company Numinus Wellness (OTCQX: NUMIF) posted its financial results for the three months ended Nov. 30, 2023. Q1 numbers show: Cash position of $3.5 (CA$4.7) million b...
Numinus Wellness reports Q1 results
Numinus Wellness press release (NUMIF): Q1 Revenue of $5.95M (+4.9% Y/Y) beats by $0.76M. 19,961 clinical appointments in Q1 2024, compared to 21,068 in Q4 2023. Average of 316.8..
Numinus Wellness Inc. Announces First Quarter Fiscal 2024 Results
Q1 Fiscal 2024 Highlights Gross profit of $2.1 million, an 18.8% increase over Q4 2023 Revenue of $5.9 million, a 3.0% decline over Q4 2023 Reduced operating expenditures of 19.9% over Q4 2023 Cash po...
Numinus to Host Q1 Fiscal 2024 Results Conference Call on January 15, 2024
VANCOUVER, BC , Jan. 2, 2024 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioural...
Cedar Clinical Research selected as clinical research site for Beckley Psytech's Phase 2b Study
VANCOUVER, BC , Dec. 15, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral...
Numinus Congratulates MAPS on its Application to the FDA for MDMA-Assisted Therapy for PTSD
VANCOUVER, BC , Dec. 13, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evide...
Numinus Reports Q4 & Full Year Fiscal 2023 Results, Including Greatly Reduced Cash Burn Rate
Psychedelic therapy clinic provider Numinus Wellness (TSX:NUMI) (OTC: NUMIF) announced fourth quarter and full year fiscal 2023 results Wednesday after market. The numbers show demonstrable growth on...
Numinus Wellness GAAP EPS of -C$0.11, revenue of C$23.18M
Numinus Wellness reports FY 2023 GAAP EPS of -C$0.11 and a revenue surge of 257.2% YoY, reaching C$23.18M.